Literature DB >> 21989772

Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process.

Annalisa Angelini1, Chiara Castellani, Barbara Ravara, Chiara Franzin, Michela Pozzobon, Regina Tavano, Luciano Dalla Libera, Emanuele Papini, Roberto Vettor, Paolo De Coppi, Gaetano Thiene, Giorgio Vescovo.   

Abstract

BACKGROUND: In this study we investigated the effect of human amniotic fluid stem (hAFS) cells and rat adipose tissue stromal vascular fraction GFP-positive cell (rSVC-GFP) therapy and the contribution of the paracrine and neurohormonal milieu to cardiac and pulmonary vascular remodeling in a rat model of pulmonary hypertension (PH) and right heart failure (RHF).
METHODS: Sprague-Dawley rats were injected with monocrotaline (MCT). Four million hAFS or rSVC-GFP cells were injected via the tail vein 3 weeks after MCT. RHF was confirmed by RV hypertrophy/dilation and by brain natriuretic peptide (BNP) level. Cytokine profile was assessed by Multiplex array. Stem cell (SC) differentiation was studied by immunofluorescence.
RESULTS: MCT rats showed eccentric RV hypertrophy with increased RV dilation (measured as right ventricular mass/right ventricular volume [RVM/RVV]: MCT, 1.46 ± 0.12; control, 2.33 ± 0.24; p = 0.01), and increased RV hypertrophy (measured as LVM/RVM: MCT, 1.58 ± 0.06; control, 2.83 ± 0.1; p < 0.00001), increased BNP (MCT, 5.2 ± 1.2; control, 1.5 ± 0.1; p < 0.001) and both pro- and anti-inflammatory cytokines. SC produced a fall of BNP (hAFS, 2.1 ± 0.7; rSVC-GFP, 1.98 ± 1.3; p < 0.001) and pro-inflammatory cytokines. Positive RV remodeling with decreased RV dilation (RVM/RVV: hAFS, 1.87 ± 0.44; rSVC-GFP, 2.12 ± 0.24; p < 0.03 and p < 0.05 vs MCT) and regression of RV hypertrophy (LVM/RVM: hAFS, 2.06 ± 0.08; rSVC-GFP, 2.16 ± 0.08; p < 0.00001 vs MCT) was seen together with a decrease in medial wall thickness of pulmonary arterioles (hAFS, 35.33 ± 2.78%; rSVC-GFP, 37.15 ± 2.92%; p = 0.0001 vs MCT).
CONCLUSIONS: SC engrafted in the lung, heart and skeletal muscle modulated the pro- and anti-inflammatory cytokine milieu, and produced a positive neurohormonal response. This was accompanied by positive cardiac and pulmonary vascular remodeling, with formation mainly of new vascular cells. 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989772     DOI: 10.1016/j.healun.2011.07.017

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  19 in total

Review 1.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

2.  The Celution® System: Automated Processing of Adipose-Derived Regenerative Cells in a Functionally Closed System.

Authors:  John K Fraser; Kevin C Hicok; Rob Shanahan; Min Zhu; Scott Miller; Douglas M Arm
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-01-01       Impact factor: 4.730

Review 3.  Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series).

Authors:  Arnoud van der Laarse; Christa M Cobbaert; Soban Umar
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  Cardiosphere-derived cells from pediatric end-stage heart failure patients have enhanced functional activity due to the heat shock response regulating the secretome.

Authors:  Sudhish Sharma; Rachana Mishra; David Simpson; Brody Wehman; Evan J Colletti; Savitha Deshmukh; Srinivasa Raju Datla; Keerti Balachandran; Yin Guo; Ling Chen; Osama T Siddiqui; Shalesh Kaushal; Sunjay Kaushal
Journal:  Stem Cells       Date:  2015-04       Impact factor: 6.277

Review 5.  Amniotic Fluid Stem Cells: A New Era in Regenerative Medicine.

Authors:  Mala Srivastava; Neha Ahlawat; Ankita Srivastava
Journal:  J Obstet Gynaecol India       Date:  2017-07-27

Review 6.  Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.

Authors:  Marek Barczyk; Matthias Schmidt; Sabrina Mattoli
Journal:  Stem Cell Rev Rep       Date:  2015-08       Impact factor: 5.739

7.  Mesenchymal stem cells attenuate vascular remodeling in monocrotaline-induced pulmonary hypertension rats.

Authors:  Jiang Xie; Dayi Hu; Lili Niu; Suping Qu; Shenghao Wang; Shuang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

Review 8.  Cellular apoptosis in the cardiorenal axis.

Authors:  Grazia Maria Virzì; Anna Clementi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

9.  The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension.

Authors:  Hyunsook Kang; Kang-Hyun Kim; Jisun Lim; You-Sun Kim; Jinbeom Heo; Jongjin Choi; Jaeho Jeong; YongHwan Kim; Seong Who Kim; Yeon-Mok Oh; Myung-Soo Choo; Jaekyoung Son; Su Jung Kim; Hyun Ju Yoo; Wonil Oh; Soo Jin Choi; Sei Won Lee; Dong-Myung Shin
Journal:  Stem Cells Dev       Date:  2015-04-09       Impact factor: 3.272

10.  The Role of Congestion in Cardiorenal Syndrome Type 2: New Pathophysiological Insights into an Experimental Model of Heart Failure.

Authors:  Annalisa Angelini; Chiara Castellani; Grazia Maria Virzì; Marny Fedrigo; Gaetano Thiene; Marialuisa Valente; Claudio Ronco; Giorgio Vescovo
Journal:  Cardiorenal Med       Date:  2015-10-31       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.